The startup develops targeted therapies for patients with rare diseases and cancer, utilizing advanced drug formulation techniques to enhance therapeutic efficacy. Their focus is on improving patient outcomes through the commercialization of specialized treatments that address unmet medical needs in oncology and rare disease sectors.
Funding
$348.5M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Patients with rare diseases and cancers often face limited treatment options and suboptimal outcomes due to the lack of targeted therapies and effective drug formulations. Existing treatments may not adequately address the underlying mechanisms of these diseases, resulting in unmet medical needs and reduced quality of life for affected individuals.
Solution
Mereo BioPharma is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for rare diseases and cancers. The company in-licenses and develops novel therapies that have already received significant investment, focusing on programs with high prevalence and retaining global or regional rights where possible. Their pipeline includes clinical-stage product candidates targeting Osteogenesis Imperfecta (OI) and Alpha-1 Antitrypsin Deficiency-associated Lung Disease (AATD-LD), as well as partnered programs for platinum-resistant ovarian cancer and acute exacerbations of chronic obstructive pulmonary disease (AECOPD). Mereo BioPharma aims to improve patient outcomes by addressing the underlying mechanisms of rare diseases and cancers with targeted therapies and strategic partnerships.
Target Audience
The primary target audience includes patients with rare diseases and cancers, as well as healthcare professionals, investors, and partners interested in novel therapies and disease-modifying treatments.
Features
- Setrusumab (UX-143): A fully humanized monoclonal antibody inhibiting sclerostin for the potential treatment of Osteogenesis Imperfecta (OI), designed to improve bone formation and strength.
- Alvelestat (MPH966): An oral drug inhibiting neutrophil elastase for the potential treatment of Alpha-1 Antitrypsin Deficiency-associated Lung Disease (AATD-LD), aiming to protect against progressive lung damage.
- Etigilimab (MPH313): An antibody against TIGIT (T-cell immunoreceptor with Ig and ITIM domains) for the potential treatment of patients with advanced or metastatic solid tumors, designed to improve the activation and effectiveness of T-cell and NK cell anti-tumor activity.
- Navicixizumab (OMP305B83): For the potential treatment of platinum-resistant ovarian cancer, partnered with OncXerna Therapeutics Inc. for further development.
- Acumapimod (BCT197): For the potential treatment of acute exacerbations of chronic obstructive pulmonary disease (“AECOPD”).
- Strategic partnerships with Ultragenyx, OncXerna Therapeutics Inc. and ReproNovo to maximize development and commercialization opportunities.